The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.
Subjects with written informed consent;
Age: 18-60 years;
Diagnosis of T1DM according to ADA criteria within 1 year prior to starting study drug;
Islet autoantibody positivity (one or more of GADA, IA-2A, ZnT8A);
Non-Type 1 Diabetes Mellitus.
Positivity for human immunodeficiency virus
Positive purified protein derivative or interferon-γ release assay suggestive of tuberculosis
Positivity for hepatitis B surface antigen And acute infections (e.g., respiratory, urinary tract, or gastrointestinal infections) must be resolved before reevaluation;